<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">IJO</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0301-4738</issn>
      <issn pub-type="epub">1998-3689</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21157079</article-id>
      <article-id pub-id-type="pmc">3032250</article-id>
      <article-id pub-id-type="publisher-id">IJO-59-62</article-id>
      <article-id pub-id-type="doi">10.4103/0301-4738.73728</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communications</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rishi</surname>
            <given-names>Pukhraj</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Venkataraman</surname>
            <given-names>Anusha</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rishi</surname>
            <given-names>Ekta</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
      </contrib-group>
      <aff id="AF0001">Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, 18, College Road, Chennai - 600 006, Tamil Nadu, India</aff>
      <author-notes>
        <corresp id="cor1">Correspondence to: Dr Pukhraj Rishi, Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, 18, College Road, Chennai - 600 006, Tamil Nadu, India. E-mail: <email xlink:href="docrishi@yahoo.co.in">docrishi@yahoo.co.in</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2011</year>
      </pub-date>
      <volume>59</volume>
      <issue>1</issue>
      <fpage>62</fpage>
      <lpage>64</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>11</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>8</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Indian Journal of Ophthalmology</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A 14-year-old girl presenting with visual loss in both eyes was diagnosed to have healed toxoplasma retinochoroiditis in the right eye with active choroidal neovascularization (CNV) secondary to toxoplasmosis in the left. She underwent combination photodynamic therapy (PDT) and intravitreal bevacizumab as primary treatment. PDT was performed as per the &#x2018;Treatment of Age-related Macular Degeneration by Photodynamic therapy&#x2019; study protocol and was followed by intravitreal bevacizumab after 2 days. CNV regressed at 8 weeks of follow-up and remained stable at 8 months of follow-up. The initial visual acuity improved from 20/120 to 20/30. Combination therapy with PDT and intravitreal bevacizumab appears to be effective in the treatment of CNV secondary to toxoplasma retinochoroiditis.</p>
      </abstract>
      <kwd-group>
        <kwd>Bevacizumab</kwd>
        <kwd>choroidal neovascularization</kwd>
        <kwd>photodynamic therapy</kwd>
        <kwd>toxoplasmosis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Ocular toxoplasmosis is an important cause of choroidal neovascularization (CNV) in the pediatric age group.[<xref ref-type="bibr" rid="CIT1">1</xref>] The development of CNV adjacent to retinochoroidal scars is a well-known late complication contributing to loss of useful vision due to foveal involvement. Treatment modalities for CNV secondary to toxoplasma retinochoroiditis include laser photocoagulation, submacular surgery, photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) agents.[<xref ref-type="bibr" rid="CIT1">1</xref>] We report a case of CNV secondary to ocular toxoplasmosis treated with a combination of verteporfin&#x2013;PDT and intravitreal bevacizumab. Combination therapy for CNV secondary to toxoplasmosis has not been reported in the past.</p>
    <sec sec-type="cases" id="sec1-1">
      <title>Case Report</title>
      <p>A 14-year-old girl presented with a 1-year history of deterioration of vision in both eyes. There were no significant ocular problems in the past. Medical and family history and systemic examination were unremarkable. On ocular examination, her best corrected visual acuity (BCVA) at presentation was CF 1 mt, N36 in the right eye and 20/120, N18 in the left eye. Biomicroscopic examination did not show any evidence of intra-ocular inflammation and the anterior segment was unremarkable in both eyes. Fundus evaluation of the right eye showed the presence of a punched-out pigmented lesion with well-demarcated borders at the macula that was suggestive of a healed toxoplasma lesion [<xref ref-type="fig" rid="F0001">Fig. 1A</xref>]. Clinical findings were confirmed on fluorescein angiography [<xref ref-type="fig" rid="F0001">Fig. 1B</xref>] and Optical coherence tomography [<xref ref-type="fig" rid="F0001">Fig. 1C</xref>]. Left eye examination not only showed a punched-out pigmented lesion at the macula but also a choroidal neovascular membrane with adjacent subretinal fluid and hemorrhage just medial to the pigmented scar [<xref ref-type="fig" rid="F0002">Fig. 2A</xref>].</p>
      <fig id="F0001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>At presentation, right eye color fundus photograph (A) reveals a punched-out pigmented lesion with well-demarcated borders at the macula suggestive of a healed toxoplasma scar. Fluorescein angiography (B) reveals staining of the retinal scar. Optical coherence tomography reveals retinal atrophy corresponding to the lesion (C)</p>
        </caption>
        <graphic xlink:href="IJO-59-62-g001"/>
      </fig>
      <fig id="F0002" position="float">
        <label>Figure 2</label>
        <caption>
          <p>At presentation, left eye color fundus photograph (A) reveals a pigmented lesion at the macula along with a choroidal neovascular membrane, adjacent subretinal hemorrhage and fluid medial to the pigmented scar. Fluorescein angiography (B, C) reveals an active, subfoveal classic choroidal neovascular membrane with profuse leakage. Blocked choroidal fluorescence due to the overlying hemorrhage is also noted. Optical coherence tomography reveals subfoveal choroidal neovascular membrane and subretinal fluid adjacent to a subretinal scar</p>
        </caption>
        <graphic xlink:href="IJO-59-62-g002"/>
      </fig>
      <p>The clinical findings were confirmed on fundus fluorescein angiography (FFA) and optical coherence tomography (OCT). The FFA of the left eye revealed an active subfoveal classic choroidal neovascular membrane with profuse leakage. Blocked choroidal fluorescence due to the overlying hemorrhage was also noted [<xref ref-type="fig" rid="F0002">Fig. 2B</xref>]. OCT revealed subfoveal choroidal neovascular membrane (CNVM) and subretinal fluid adjacent to a subretinal scar [<xref ref-type="fig" rid="F0002">Fig. 2C</xref>]. The routine hemogram, kidney function tests and liver function tests were within the normal range. Mantoux test was negative and chest X-ray was normal. The anti-toxoplasma IgM titer was negative; IgG titer was however equivocal. A diagnosis of healed toxoplasma retinochoroiditis in the right eye and subfoveal CNVM secondary to toxoplasma retinochoroiditis in the left eye was arrived at. The nature of the disease and treatment options were explained. The patient underwent verteporfin-PDT as per the &#x2018;Treatment of Age-related Macular Degeneration by Photodynamic therapy&#x2019; protocol.[<xref ref-type="bibr" rid="CIT2">2</xref>] This was followed by an intravitreal injection of bevacizumab (1.25 mg/0.05 ml) after 2 days.</p>
      <p>At 8 weeks follow-up, the CNV showed regression with no evidence of subretinal fluid or hemorrhage on clinical examination or OCT. The BCVA improved to 20/30, N6 and the fundus remained stable up to the eighth month of follow-up [<xref ref-type="fig" rid="F0003">Fig. 3</xref>]. No adverse ocular or systemic event related to the treatment procedure was encountered.</p>
      <fig id="F0003" position="float">
        <label>Figure 3</label>
        <caption>
          <p>At 8 months of follow-up, color fundus photograph (A) reveals a regressed choroidal neovascular membrane. Optical coherence tomography reveals (B) a high reflective subfoveal scar</p>
        </caption>
        <graphic xlink:href="IJO-59-62-g003"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="sec1-2">
      <title>Discussion</title>
      <p>The natural history of CNV secondary to toxoplasmosis reveals a poor visual prognosis.[<xref ref-type="bibr" rid="CIT3">3</xref>&#x2013;<xref ref-type="bibr" rid="CIT5">5</xref>] The CNV originates adjacent to the retinochoroidal scars and leads to central visual loss due to foveal involvement. The different treatment modalities described for CNV secondary to toxoplasmosis in children include laser photocoagulation, submacular surgery, PDT and anti-VEGF agents.[<xref ref-type="bibr" rid="CIT1">1</xref>] Laser photocoagulation is no longer preferred as it results in a permanent scotoma. Uemura <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT6">6</xref>] assessed the efficacy of surgical removal of membranes in a series of 14 children with subfoveal CNV of which one was secondary to toxoplasmosis. The initial visual acuity of 20/100 in this patient improved to a final visual acuity of 20/20 at 27 months follow-up. The favorable outcome is attributed to the solitary subretinal site of ingrowth that is easily amenable to surgery.[<xref ref-type="bibr" rid="CIT7">7</xref>] However, surgery can have its own complications and does not prevent recurrences.</p>
      <p>The use of verteporfin&#x2013;PDT, although initially used for the treatment of age-related macular degeneration and myopic CNV, has now been extended beyond these indications to inflammatory and infectious etiologies. Mauget Faysse <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT8">8</xref>] have found verteporfin&#x2013;PDT to be efficacious for subfoveal CNV associated with toxoplasma retinochoroiditis. In their study of eight patients, the mean visual acuity improved from 20/225 to 20/123 during a mean follow-up period of 25 months. Ben Yahia <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT9">9</xref>] recently reported the resolution of two CNVMs secondary to toxoplasma retinochoroiditis following administration of a single intravitreal injection of bevacizumab as primary treatment or as rescue treatment following unsuccessful PDT.</p>
      <p>There is however no report of any patient with CNV secondary to toxoplasmosis who has been managed with combination PDT and intravitreal bevacizumab as a primary treatment. The combined regime is postulated to have a beneficial synergistic effect that could reduce the need for repeated injections. Combination therapy using PDT and bevacizumab as the first-line management in such cases could be a viable option.[<xref ref-type="bibr" rid="CIT10">10</xref>] Larger studies with longer follow-up may reveal that visual outcome with combination therapy could be better than PDT alone.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="CIT1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sivaprasad</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>AT</given-names>
            </name>
          </person-group>
          <article-title>Choroidal neovascularisation in children</article-title>
          <source>Br J Ophthalmol</source>
          <year>2008</year>
          <volume>92</volume>
          <fpage>451</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">18369058</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT2">
        <label>2</label>
        <element-citation publication-type="journal">
          <article-title>Treatment of Age related macular degeneration with photodynamic therapy (TAP) study group: Photodynamic therapy of subfoveal CNV in ARMD with verteporfin; One year results of 2 Randomized clinical trials- TAP report</article-title>
          <source>Arch Ophthalmol</source>
          <year>1999</year>
          <volume>117</volume>
          <fpage>1329</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">10532441</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atmaca</surname>
              <given-names>Ls</given-names>
            </name>
            <name>
              <surname>Simsek</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Batioglu</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Clinical features and prognosis in ocular toxoplasmosis</article-title>
          <source>Jpn J Ophthalmol</source>
          <year>2004</year>
          <volume>48</volume>
          <fpage>386</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">15295668</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Augsburger</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Benson</surname>
              <given-names>WE</given-names>
            </name>
          </person-group>
          <article-title>Subretinal neovascularisation in chronic uveitis</article-title>
          <source>Albrecht Von Graefes Arch Klin Exp Ophthalmol</source>
          <year>1980</year>
          <volume>215</volume>
          <fpage>43</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">6161555</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goshorn</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Hoover</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Eller</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Friberg</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Jarrett</surname>
              <given-names>WH</given-names>
              <suffix>2nd</suffix>
            </name>
            <name>
              <surname>Sorr</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Subretinal revascularization in children and adolescents</article-title>
          <source>J Paediatr Ophthalmol Strabismus</source>
          <year>1995</year>
          <volume>32</volume>
          <fpage>178</fpage>
          <lpage>82</lpage>
        </element-citation>
      </ref>
      <ref id="CIT6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uemura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Visual Outcome after Surgical Removal of Choroidal Neovascularization in Pediatric Patients</article-title>
          <source>Arch Ophthalmol</source>
          <year>2000</year>
          <volume>118</volume>
          <fpage>1373</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">11030819</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melberg</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>The surgical removal of subfoveal choroidal neovascularisation. Ingrowth as a site of predictor of visual outcome</article-title>
          <source>Retina</source>
          <year>1996</year>
          <volume>16</volume>
          <fpage>190</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">8789856</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mauget-Fa&#xFF;sse</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mimoun</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ruiz-Moreno</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Quaranta-El Maftouhi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Laey</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Postelmans</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Verteporfin photodynamic therapy for choroidal neovascularisation associated with toxoplasma retinochoroiditis</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>396</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="pmid">16603957</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ben Yahia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Herbort</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Jenzeri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hmidi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Attia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Messaoud</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis</article-title>
          <source>International Ophthalmol</source>
          <year>2008</year>
          <volume>28</volume>
          <fpage>311</fpage>
          <lpage>6</lpage>
        </element-citation>
      </ref>
      <ref id="CIT10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhalla</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Blinder</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>EH</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Mittra</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Tewari</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age related macular degeneration</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>988</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">17151484</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
